Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
E-pub ahead of print

Seroprevalence of SARS-CoV-2 antibodies and reduced risk of reinfection through 6 months: a Danish observational cohort study of 44,000 healthcare workers

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Iversen, Kasper ; Kristensen, Jonas Henrik ; Hasselbalch, Rasmus Bo ; Pries-Heje, Mia ; Nielsen, Pernille Brok ; Knudsen, Andreas Dehlbæk ; Fogh, Kamille ; Norsk, Jakob Boesgaard ; Andersen, Ove ; Fischer, Thea Køhler ; Juul Jensen, Claus Antonio ; Torp-Pedersen, Christian ; Rungby, Jørgen ; Ditlev, Sisse Bolm ; Hageman, Ida ; Møgelvang, Rasmus ; Gybel-Brask, Mikkel ; Dessau, Ram B ; Sørensen, Erik ; Harritshøj, Lene ; Folke, Fredrik ; Sten, Curt ; Engel Møller, Maria Elizabeth ; Benfield, Thomas ; Ullum, Henrik ; Jørgensen, Charlotte Sværke ; Erikstrup, Christian ; Ostrowski, Sisse R ; Nielsen, Susanne Dam ; Bundgaard, Henning. / Seroprevalence of SARS-CoV-2 antibodies and reduced risk of reinfection through 6 months : a Danish observational cohort study of 44,000 healthcare workers. I: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2021.

Bibtex

@article{8a9fcb80dd6445df86da299e1d35cdd8,
title = "Seroprevalence of SARS-CoV-2 antibodies and reduced risk of reinfection through 6 months: a Danish observational cohort study of 44,000 healthcare workers",
abstract = "OBJECTIVES: Antibodies to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) are a key factor in protecting against coronavirus disease 2019 (COVID-19). We examined longitudinal changes in seroprevalence in healthcare workers (HCWs) in Copenhagen and the protective effect of antibodies against SARS-CoV-2.METHODS: In this prospective study, screening for antibodies against SARS-CoV-2 (ELISA) was offered to HCWs three times over 6 months. HCW characteristics were obtained by questionnaires. The study was registered at ClinicalTrials.gov, NCT04346186.RESULTS: From April to October 2020 we screened 44 698 HCWs, of whom 2811 were seropositive at least once. The seroprevalence increased from 4.0% (1501/37 452) to 7.4% (2022/27 457) during the period (p < 0.001) and was significantly higher than in non-HCWs. Frontline HCWs had a significantly increased risk of seropositivity compared to non-frontline HCWs, with risk ratios (RRs) at the three rounds of 1.49 (95%CI 1.34-1.65, p < 0.001), 1.52 (1.39-1.68, p < 0.001) and 1.50 (1.38-1.64, p < 0.001). The seroprevalence was 1.42- to 2.25-fold higher (p < 0.001) in HCWs from dedicated COVID-19 wards than in other frontline HCWs. Seropositive HCWs had an RR of 0.35 (0.15-0.85, p 0.012) of reinfection during the following 6 months, and 2115 out of 2248 (95%) of those who were seropositive during rounds one or two remained seropositive after 4-6 months. The 133 of 2248 participants (5.0%) who seroreverted were slightly older and reported fewer symptoms than other seropositive participants.CONCLUSIONS: HCWs remained at increased risk of infection with SARS-CoV-2 during the 6-month period. Seropositivity against SARS-CoV-2 persisted for at least 6 months in the vast majority of HCWs and was associated with a significantly lower risk of reinfection.",
keywords = "COVID, Healthcare workers, Immune response, SARS-CoV-2, Seroprevalence",
author = "Kasper Iversen and Kristensen, {Jonas Henrik} and Hasselbalch, {Rasmus Bo} and Mia Pries-Heje and Nielsen, {Pernille Brok} and Knudsen, {Andreas Dehlb{\ae}k} and Kamille Fogh and Norsk, {Jakob Boesgaard} and Ove Andersen and Fischer, {Thea K{\o}hler} and {Juul Jensen}, {Claus Antonio} and Christian Torp-Pedersen and J{\o}rgen Rungby and Ditlev, {Sisse Bolm} and Ida Hageman and Rasmus M{\o}gelvang and Mikkel Gybel-Brask and Dessau, {Ram B} and Erik S{\o}rensen and Lene Harritsh{\o}j and Fredrik Folke and Curt Sten and {Engel M{\o}ller}, {Maria Elizabeth} and Thomas Benfield and Henrik Ullum and J{\o}rgensen, {Charlotte Sv{\ae}rke} and Christian Erikstrup and Ostrowski, {Sisse R} and Nielsen, {Susanne Dam} and Henning Bundgaard",
note = "Copyright {\textcopyright} 2021. Published by Elsevier Ltd.",
year = "2021",
month = sep,
day = "17",
doi = "10.1016/j.cmi.2021.09.005",
language = "English",
journal = "Clinical Microbiology and Infection",
issn = "1198-743X",
publisher = "Wiley-Blackwell Publishing Ltd",

}

RIS

TY - JOUR

T1 - Seroprevalence of SARS-CoV-2 antibodies and reduced risk of reinfection through 6 months

T2 - a Danish observational cohort study of 44,000 healthcare workers

AU - Iversen, Kasper

AU - Kristensen, Jonas Henrik

AU - Hasselbalch, Rasmus Bo

AU - Pries-Heje, Mia

AU - Nielsen, Pernille Brok

AU - Knudsen, Andreas Dehlbæk

AU - Fogh, Kamille

AU - Norsk, Jakob Boesgaard

AU - Andersen, Ove

AU - Fischer, Thea Køhler

AU - Juul Jensen, Claus Antonio

AU - Torp-Pedersen, Christian

AU - Rungby, Jørgen

AU - Ditlev, Sisse Bolm

AU - Hageman, Ida

AU - Møgelvang, Rasmus

AU - Gybel-Brask, Mikkel

AU - Dessau, Ram B

AU - Sørensen, Erik

AU - Harritshøj, Lene

AU - Folke, Fredrik

AU - Sten, Curt

AU - Engel Møller, Maria Elizabeth

AU - Benfield, Thomas

AU - Ullum, Henrik

AU - Jørgensen, Charlotte Sværke

AU - Erikstrup, Christian

AU - Ostrowski, Sisse R

AU - Nielsen, Susanne Dam

AU - Bundgaard, Henning

N1 - Copyright © 2021. Published by Elsevier Ltd.

PY - 2021/9/17

Y1 - 2021/9/17

N2 - OBJECTIVES: Antibodies to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) are a key factor in protecting against coronavirus disease 2019 (COVID-19). We examined longitudinal changes in seroprevalence in healthcare workers (HCWs) in Copenhagen and the protective effect of antibodies against SARS-CoV-2.METHODS: In this prospective study, screening for antibodies against SARS-CoV-2 (ELISA) was offered to HCWs three times over 6 months. HCW characteristics were obtained by questionnaires. The study was registered at ClinicalTrials.gov, NCT04346186.RESULTS: From April to October 2020 we screened 44 698 HCWs, of whom 2811 were seropositive at least once. The seroprevalence increased from 4.0% (1501/37 452) to 7.4% (2022/27 457) during the period (p < 0.001) and was significantly higher than in non-HCWs. Frontline HCWs had a significantly increased risk of seropositivity compared to non-frontline HCWs, with risk ratios (RRs) at the three rounds of 1.49 (95%CI 1.34-1.65, p < 0.001), 1.52 (1.39-1.68, p < 0.001) and 1.50 (1.38-1.64, p < 0.001). The seroprevalence was 1.42- to 2.25-fold higher (p < 0.001) in HCWs from dedicated COVID-19 wards than in other frontline HCWs. Seropositive HCWs had an RR of 0.35 (0.15-0.85, p 0.012) of reinfection during the following 6 months, and 2115 out of 2248 (95%) of those who were seropositive during rounds one or two remained seropositive after 4-6 months. The 133 of 2248 participants (5.0%) who seroreverted were slightly older and reported fewer symptoms than other seropositive participants.CONCLUSIONS: HCWs remained at increased risk of infection with SARS-CoV-2 during the 6-month period. Seropositivity against SARS-CoV-2 persisted for at least 6 months in the vast majority of HCWs and was associated with a significantly lower risk of reinfection.

AB - OBJECTIVES: Antibodies to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) are a key factor in protecting against coronavirus disease 2019 (COVID-19). We examined longitudinal changes in seroprevalence in healthcare workers (HCWs) in Copenhagen and the protective effect of antibodies against SARS-CoV-2.METHODS: In this prospective study, screening for antibodies against SARS-CoV-2 (ELISA) was offered to HCWs three times over 6 months. HCW characteristics were obtained by questionnaires. The study was registered at ClinicalTrials.gov, NCT04346186.RESULTS: From April to October 2020 we screened 44 698 HCWs, of whom 2811 were seropositive at least once. The seroprevalence increased from 4.0% (1501/37 452) to 7.4% (2022/27 457) during the period (p < 0.001) and was significantly higher than in non-HCWs. Frontline HCWs had a significantly increased risk of seropositivity compared to non-frontline HCWs, with risk ratios (RRs) at the three rounds of 1.49 (95%CI 1.34-1.65, p < 0.001), 1.52 (1.39-1.68, p < 0.001) and 1.50 (1.38-1.64, p < 0.001). The seroprevalence was 1.42- to 2.25-fold higher (p < 0.001) in HCWs from dedicated COVID-19 wards than in other frontline HCWs. Seropositive HCWs had an RR of 0.35 (0.15-0.85, p 0.012) of reinfection during the following 6 months, and 2115 out of 2248 (95%) of those who were seropositive during rounds one or two remained seropositive after 4-6 months. The 133 of 2248 participants (5.0%) who seroreverted were slightly older and reported fewer symptoms than other seropositive participants.CONCLUSIONS: HCWs remained at increased risk of infection with SARS-CoV-2 during the 6-month period. Seropositivity against SARS-CoV-2 persisted for at least 6 months in the vast majority of HCWs and was associated with a significantly lower risk of reinfection.

KW - COVID

KW - Healthcare workers

KW - Immune response

KW - SARS-CoV-2

KW - Seroprevalence

UR - http://www.scopus.com/inward/record.url?scp=85116788811&partnerID=8YFLogxK

U2 - 10.1016/j.cmi.2021.09.005

DO - 10.1016/j.cmi.2021.09.005

M3 - Journal article

C2 - 34543759

JO - Clinical Microbiology and Infection

JF - Clinical Microbiology and Infection

SN - 1198-743X

ER -

ID: 67655661